Pathogen Reduction Will Not Replace Screening In Near Term – FDA’s Epstein
This article was originally published in The Gray Sheet
Executive Summary
Blood pathogen reduction technology may benefit only non-immunosuppressed patients if FDA determines that the inactivation agents pose a toxicological risk
You may also be interested in...
Vitex Inactine Surgery Study On Schedule Despite Suspension Of Chronic Trial
Vitex expects to complete a Phase III trial of its Inactine pathogen inactivation system for red blood cells used during surgery by 2005, even though the firm has halted a separate Phase III study in chronic transfusions
Vitex Inactine Surgery Study On Schedule Despite Suspension Of Chronic Trial
Vitex expects to complete a Phase III trial of its Inactine pathogen inactivation system for red blood cells used during surgery by 2005, even though the firm has halted a separate Phase III study in chronic transfusions
Cerus Pathogen Inactivation Trial Delay Alters Landscape For Vitex, Navigant
Uncertainty over Baxter/Cerus' Intercept red blood cell pathogen reduction program may benefit competitor Vitex, which is pursuing the same indication for its Inactine device